Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
----------
AIM - WINNERS
----------
Allergy Therapeutics PLC, up 22% at 1.82 pence, 12-month range 0.37p-7.37p. The commercial biotechnology firm says its "pivotal" phase three trial evaluating its subcutaneous grass allergy immunotherapy candidate meets its primary endpoint. The G306 trial of Grass MATA MPL shows a statistically significant superiority of the treatment when compared to placebo, by reducing the Combined Symptom & Medication Score during the peak pollen season. Top line analysis will be available in mid-December. "The completion of the G306 study is an important milestone in our efforts to register this innovative treatment for the benefit of the millions of patients affected by grass allergies," says CEO Manuel Llobet.
----------
DP Poland Ltd, up 11% at 8.89 pence, 12-month range 6.10p-9.80p. The franchise in Poland and Croatia for Domino's Pizza reports robust sales in the third quarter. Like-for-like system sales in Poland rise 14% in the third quarter, and 35% in October to a new monthly record. "We are seeing the benefits of our focus to build a High Volume Mentality business; delivering a compelling value proposition for our customers based on fantastic quality pizza delivered quickly," CEO Nils Gornall says. He adds that the Croatian business also continues to trade well, with the most recently opened store already surpassing initial sales expectations.
----------
AIM - LOSERS
----------
Horizonte Minerals PLC, down 46% at 10.14p, 12-month range 9.0p-172.00p. The nickel developer says it plans to reduce construction activities at its Araguaia nickel asset in Brazil to only those that are critical work streams. Says it should have sufficient working capital until around mid-December, and is advancing discussions with suppliers, as well as other cash-preserving measures, to extend its cash runway. Financing discussions with shareholders and lenders continue. "While work on the funding solution continues, we have elected to focus capital and human resources on the critical work packages. This work is planned is to ensure that we are well-positioned to resume full construction activities post receipt of the funding to benefit stakeholders and our community alike," says CEO Jeremy Martin.
----------
Renalytix PLC, down 29% at 26.74p, 12-month range 25p-155p. The London-based kidney health-focused diagnostics company's shares hit new lows on disappointing first-quarter results for the three months to September. Says revenue halves to USD459,000 from USD969,000 a year before, as its pretax loss narrows to USD10.2 million from USD12.0 million. The firm had cash and cash equivalents of USD13.9 million at the end of September, compared to USD24.7 million at the end of June.
----------
By Elizabeth Winter, Alliance News senior markets reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
